Abstract
The clinical and anti-inflammatory effects of a single treatment of 0.4 mg meloxicam/kg bodyweight on pigs that had been challenged with Escherichia coli endotoxin were investigated. Significantly lower total clinical scores were recorded in pigs treated with meloxicam than in pigs treated with a placebo. Significantly higher mean serum concentrations of thromboxane B(2) were also recorded in pigs treated with a placebo for up to 24 hours after the challenge. The serum concentrations of acute phase proteins and specific antibody titres to E coli lipopolysaccharide were unaffected by the meloxicam. The meloxicam treatment was well tolerated.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Acute-Phase Proteins / analysis
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Antibodies, Bacterial / blood
-
Endotoxemia / drug therapy
-
Endotoxemia / veterinary*
-
Escherichia coli / immunology
-
Escherichia coli Infections / drug therapy
-
Escherichia coli Infections / veterinary*
-
Female
-
Immunoglobulin G / blood
-
Lipopolysaccharides / immunology
-
Male
-
Meloxicam
-
Single-Blind Method
-
Swine
-
Swine Diseases / drug therapy*
-
Thiazines / therapeutic use*
-
Thiazoles / therapeutic use*
-
Thromboxane B2 / blood
-
Treatment Outcome
Substances
-
Acute-Phase Proteins
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Bacterial
-
Immunoglobulin G
-
Lipopolysaccharides
-
Thiazines
-
Thiazoles
-
Thromboxane B2
-
Meloxicam